Ignite Creation Date:
2024-05-06 @ 11:16 AM
Last Modification Date:
2024-10-26 @ 12:42 PM
Study NCT ID:
NCT03473691
Status:
WITHDRAWN
Last Update Posted:
2018-06-01
First Post:
2018-02-14
Brief Title:
Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer
Sponsor:
University of Virginia
Organization:
University of Virginia
Organization Data
Organization:
University of Virginia
Class:
OTHER
Study ID:
TBDBreast50
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
University of Virginia
Lead Sponsor Class:
OTHER
Responsible Party:
Patrick Dillon MD
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
University of Virginia
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Celldex Therapeutics | INDUSTRY |